Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
4306studies shown
Showing 2,677-2,688 of 4,306
Drug study icon
TerminatedNCT00366704

Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Little Rock
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugA study involving a medication or substance.From 18 Years to 65 Years
Countries
United States
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Condition
Schizophrenia
Drug study icon
TerminatedNCT00366327

Study Evaluating Bifeprunox in people with Schizophrenia.

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Little Rock
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 66 Years
Countries
United States
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Condition
Schizophrenia
Drug study icon
WithdrawnNCT00781794

Study Evaluating The Effects Of Single Oral Doses Of NSA-789 On Auditory P50 Suppression In Schizophrenic Patients

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Glendale
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 55 Years
Countries
United States, France
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Condition
Schizophrenia
Drug study icon
CompletedNCT00563706

Study Evaluating Vabicaserin in Subjects With Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Little Rock
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States, Canada
Sponsor
Pfizer
Condition
Schizophrenia
Drug study icon
CompletedNCT00894842

a Neurocognition Enhancing Agent in people with Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In Singapore
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 21 Years to 65 Years
Countries
Singapore
Sponsor
National Research Foundation, Singapore
Condition
Schizophrenia
Drug study icon
CompletedNCT00086593

An FDA-approved Drug As Additional Therapy In people with Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Little Rock
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States, Canada, United Kingdom
Sponsor
GlaxoSmithKline
Condition
Schizophrenia
Drug study icon
CompletedNCT00392197

Aripiprazole in people with Schizophrenia- Effects on Glucose Metabolism-

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Hokkaido Region
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugOver 16 Years
Countries
Japan
Sponsor
Otsuka Pharmaceutical Co., Ltd.
Condition
Schizophrenia
Drug study icon
CompletedNCT04306146

CAD-9303 in Subjects With Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Long Beach
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 50 Years
Countries
United States
Sponsor
Cadent Therapeutics
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.